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ABSTRACT 1 
Oncogene-specific down-regulation mediated by RNA interference (RNAi) is a 2 
promising avenue for cancer therapy. In addition to specific gene silencing, in 3 
vivo RNAi treatment with short interfering RNAs (siRNAs) can initiate immune 4 
activation through innate immune receptors including Toll-like receptors, 5 
(TLRs) 7 and 8. Two recent studies have shown that activation of innate 6 
immunity by addition of tri-phosphate motifs to oncogene-specific siRNAs, or 7 
by co-treatment with CpG oligos, can potentiate siRNA anti-tumor effects. To 8 
date, there are no reports on applying such approach against Human 9 
Papillomavirus(HPV)-driven cancers. Here, we characterized the anti-tumor 10 
effects of non-modified siRNAs that can target a specific oncogene and/or 11 
recruit the innate immune system against HPV-driven tumors. Following the 12 
characterization of silencing efficacy and TLR7 immunostimulatory potential of 13 
15 siRNAs targeting the HPV type 16 E6/E7 oncogenes, we identified a 14 
bifunctional siRNA sequence that displayed both potent gene silencing and 15 
active immunostimulation effect. In vivo systemic administration of this siRNA 16 
resulted in reduced growth of established TC-1 tumors in C57BL/6 mice. 17 
Ablation of TLR7 recruitment via 2'O-methyl modification of the oligo 18 
backbone reduced these anti-tumor effects. Further, a highly 19 
immunostimulatory, but non-HPV targeting siRNA was also able to exert anti-20 
tumoral effects although for less prolonged time compared to the bifunctional 21 
siRNA. Collectively, our work demonstrates for the first time that siRNA-22 
induced immunostimulation can have anti-tumoral effects against HPV-driven 23 
tumors in vivo, even independent of gene silencing efficacy. 24 
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INTRODUCTION 1 
Cancer formation is the result of an accumulation of numerous, ongoing genetic and 2 
epigenetic changes, and it is this complexity that allows cancer cells to escape 3 
monotherapy. Consequently, much effort has gone into developing a single-molecule 4 
with multiple functions as an anti-cancer strategy. SiRNA-driven RNA interference 5 
has received positive attention in this regard 1-3, as in addition to anti-tumor effects 6 
through oncogene silencing, there is a growing body of evidence suggesting that 7 
innate immune activation can increase the anti-tumor effects of siRNA 4, 5. Hence, 8 
this approach offers great promise as an anti-cancer therapy, either alone or as a co-9 
treatment.  10 
 11 
SiRNAs were originally thought to escape innate immune recruitment, however they 12 
are now known to be potent activators of several innate immune sensors including 13 
TLR7. In both human and mouse, TLR7 senses both siRNAs and single-stranded 14 
RNAs in a sequence-specific manner 6-8, which leads to the production of several 15 
pro-inflammatory cytokines, such as IFNĮ 6, 8. IFNĮ has anti-proliferative abilities and 16 
is widely used in the treatment of a range of cancers including renal cell carcinoma, 17 
melanoma and a range of hemopoetic malignancies (as reviewed in Mitchell 9). IFNĮ 18 
is also used in the treatment of genital warts and cervical intraepithelial lesion (CIN) 19 
caused by HPV infection 10-12. Moreover, evidence suggests that induction of IFNĮ by 20 
TLRs is immunomodulatory by activating natural killer (NK) cells, macrophages and 21 
dendritic cells (DC) 13, 14.  IFNĮ-dependent DC maturation subsequently promotes 22 
maturation of antigen-presenting cells (APC) 15,  accelerating tumor cells’ clearance 23 
by regulating T-cell response 16. Hence, induction of Type I IFN such as IFNĮ links 24 
the innate and adaptive immune responses beneficial as an anti-tumor strategy.  25 
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 1 
SiRNA itself has potent anti-tumor activity due to the direct down-modulation of 2 
target genes such as HPV E6 and E7 1, 17, 18 and such control of tumors is known to 3 
occur in the absence of measurable innate immune activation 3. Due to the plasticity 4 
of cancer cells, it is thought that developing ‘bifunctional’ siRNAs that can both 5 
silence target genes and activate innate immune responses would elicit a more 6 
potent anti-cancer response which is less susceptible to therapeutic escape. 7 
Evidence of siRNA bifunctionality yielding an improved anti-tumor effect was recently 8 
demonstrated by Poeck et al 4, where innate immune activation relied on the 9 
recruitment of RIG-I by 5’-triphosphate-siRNA. Using a slightly different approach, 10 
Kortylewski et al have shown that combining STAT3 siRNA with CpG oligo DNA, a 11 
potent TLR9 agonist, yielded potent anti-tumor effects via activation of tumor-12 
resident macrophages and restoration of normal immune function5. Despite this 13 
progress, anti-tumor strategies using siRNA to both silence oncogenes and recruit 14 
TLR7 are still ill-defined. To date there is no knowledge of whether siRNA 15 
bifunctionality could be exploited to treat HPV-driven tumors.  16 
 17 
In this work we investigated the use of unmodified siRNAs in combination with innate 18 
immune recruitment for the treatment of tumors driven by HPV where cancer survival 19 
is entirely reliant on the expression of E6/E7 oncogenes 19. It has been previously 20 
shown that the loss of E6/E7 expression in various cervical cancer cell lines via RNAi 21 
is a potent inducer of apoptosis in vitro 17, 18, 20, 21. We studied the contribution of 22 
immunostimulatory properties of siRNAs on E6/E7 driven tumor development. By 23 
showing that siRNA-induced immunostimulation via TLR7 has a significant anti-24 
tumor effect, even in the absence of specific gene silencing, our in vivo findings 25 
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show for the first time that bifunctionality improves overall siRNA anti-tumor effects. 1 
  2 
RESULTS 3 
Selection of siRNAs against HPV16 E6/E7 4 
In this study we investigated whether bifunctional siRNAs, those able to silence 5 
target genes and stimulate TLRs, were more potent anti-cancer agents than non-6 
stimulating siRNAs. We synthesized 15 dicer-substrate siRNAs (D-siRNAs) spanning 7 
the entire HPV16 E6/E7 mRNA (Supplementary Table 1). These D-siRNAs were 25 8 
and 27bp for the sense and antisense strand respectively and were designed using 9 
the parameters previously outlined, which result in increased silencing efficacy 10 
through enhanced strand selection and RNA-induced silencing complex (RISC) 11 
loading 22, 23. We tested these D-siRNAs on HPV16 E6/E7 mRNA in order to assess 12 
their silencing ability. As E6 and E7 are expressed from the same mRNA19, RNAi 13 
targeting affects both genes. Caski cells (an HPV 16-positive human cervical cancer 14 
cell line) were transfected with 40nM D-siRNAs for 4 hours, collected at 20 hours 15 
after transfection, and E6/E7 levels were measured by quantitative real-time PCR 16 
(qRT-PCR) normalized against ȕ-actin. Most D-siRNAs were able to down-regulate 17 
HPV16 E6/E7 mRNA, with five (IDT-3, -4, -12, -13, and -15) exhibiting potent 18 
knockdown (Figure 1a). These five D-siRNAs were further tested for their knockdown 19 
ability using a similar protocol in the murine lung epithelial cell line, TC-1, which also 20 
expresses HPV16 E6/E7 24. As TC-1 cells are syngeneic with C57BL/6 mice, this 21 
allows us to test treatments in vivo using mouse models with a fully functional 22 
immune system. Reproducing the results from the assay on Caski cells, all 5 siRNAs 23 
showed significant gene knockdown in TC-1 cells, however at a slightly lower 24 
efficacy (Figure 1b and Supplementary Figure S1a).  25 
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 1 
Immunostimulatory profiles of D-siRNAs are sequence-dependent 2 
It has been previously shown that engagement of TLR7 by siRNAs results in the 3 
production of IFNĮ from pDCs 6, 7, and that TLR7 sensing of RNA is conserved 4 
between human and mouse 8, 25, 26. To test the ability of these siRNAs to engage 5 
TLR7/8 and induce an innate immune response, we first measured TLR7 6 
engagement by observing the release of IFNĮ from primary human PBMCs following 7 
endosomal uptake of siRNAs (Figure 1c). PBMCs were collected from healthy male 8 
donors and stimulated with 90nM siRNA, delivered via DOTAP, for 16 hours before 9 
supernatants were collected and IFNĮ detected by ELISA. We observed a wide 10 
range of IFNĮ induction following siRNA stimulation of these cells (Figure 1c). 11 
Amongst the D-siRNAs previously identified as having potent silencing efficacy, IDT-12 
4 stimulated the highest level of IFNĮ release; IDT-15 gave an intermediate 13 
response, and IDTs-3, -12, and -13 induced low IFNĮ productions. From these RNAi 14 
and immunostimulatory profiles, IDT-4 was identified as a “bifunctional” D-siRNA for 15 
its ability to recruit RNAi and facilitate TLR7 activation.  16 
 17 
Modification to D-siRNA removes TLR7 activation but retains RNAi. 18 
In order to delineate between the relative contribution of RNAi and that of innate 19 
immunity in the putative anti-tumoral effects of IDT-4, we synthesized a modified 20 
version of the siRNA, IDT-4m7, with 2’-O-methyl (2'OMe) modifications to the guide 21 
strand (Supplementary Table 2).  Addition of 2’-O-methyl groups to siRNA has been 22 
shown to abolish TLR7 recruitment 3, 27. To test the ability of these siRNAs to activate 23 
TLR7 in mouse, we stimulated mouse bone marrow macrophages (BMMs) with each 24 
siRNA and measured the induction of TNFĮ. We utilized mouse BMMs as it has 25 
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been reported that ssRNAs/siRNAs delivered using DOTAP-based agents relies 1 
exclusively on TLR7 in mouse cells, due to lack of mouse TLR8 response to RNA 2 
agonists 6, 8. We observed that while IDT-4 maintained highest immunostimulation in 3 
levels of TNFĮ, 2'OMe modification of IDT-4 ablated TLR-activating ability, giving 4 
background levels of TNFĮ (Figure 2a). To confirm TLR7 recruitment by these 5 
siRNAs, we measured the levels of TNFĮ in immortalized TLR7-/- and TLR7+/+ BMMs 6 
28. In TLR7-/- cells, IDT-4-driven cytokine production levels were similar to those 7 
obtained with IDT-4m7 (Figure 2b). However, immortalized TLR7+/+ BMMs 8 
maintained similar immunostimulation profiles as seen in mouse BMMs (Figure 2c), 9 
with IDT-4 producing a greater immunostimulatory effect than IDT-4m7. In order to  10 
test whether modification altered RNAi ability, we then quantified the mRNA 11 
knockdown level of IDT-4m7 using qRT-PCR (Figure 2d) following transfection of 12 
TC-1 cells as described above. We observed that IDT-4m7 retained RNAi ability and 13 
was able to significantly knockdown HPV16 E6/E7, albeit with a 13% reduction of 14 
efficacy as compared to IDT-4 (Figure 2d). 15 
 16 
Induction of IFNĮ is transient in vivo 17 
To confirm whether the activation of TLR7 by D-siRNAs observed in vitro would also 18 
occur in vivo, we measured IFNĮ levels in serum collected from mice at 4, 8, 24, and 19 
48 hours post I.V. injection of siRNA (40µg/mouse) complexed in liposomes. The 20 
method for siRNA-encapsulated liposomes preparation was previously established in 21 
our laboratory 29. All siRNAs tested induced IFNĮ at 4 hours to varying degrees, 22 
while the empty liposomes used as our vector for systemic delivery did not (Figure 23 
2e). The level of IFNĮ induction peaked at 4 hours and then decreased over time, 24 
suggesting a transient response. In agreement with our previous in vitro results, IDT-25 
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4 induced the highest levels of IFNĮ, with cytokine levels remaining high at 8 hours. 1 
We also tested BP1 Mod2 siRNA, previously shown to be a strong IFNĮ inducer in 2 
vivo 7. Although BP1 Mod2 induced IFNĮ to lower levels compared to IDT-4, IFNĮ 3 
was still detectable at 24 hours post-injection. The scrambled siRNA control also 4 
induced a low level of IFNĮ at 4 and 8 hours, but at significantly reduced levels 5 
compared to all other siRNAs. Induction of IFNĮ was not detectable at 48 hours post-6 
injection in all siRNAs, showing that IFNĮ induction in vivo by siRNAs was not 7 
sustained.  8 
 9 
TLR7 activation by siRNAs leads to activation of immune response cells 10 
Immunomodulation by TLRs has been shown to activate dendritic cells (DCs) 30, 31, 11 
natural killer (NK) cells 32 and T cells 33, which are important mediators for immune 12 
clearance of tumor cells. Prior to using our siRNAs against HPV-driven tumors in 13 
vivo, we sought to observe activation of these immune cells consistent with TLR7 14 
activation by IDT-4 as opposed to IDT-4m7. We stimulated splenocytes from 15 
C57BL/6 mice with siRNAs IDT-4 and IDT-4m7 complexed in the liposomes 29 to be 16 
used for in vivo I.V. injection, and measured expression of CD86 in DCs, and CD69 17 
in NK and T-cells. CD86 expression following IDT-4 stimulation was doubled that of 18 
IDT-4m7, and similar to the expression of synthetic TLR7 agonist Imiquimod (Figure 19 
3a). Similar results were observed for CD69 activation in NK and T-cells (Figure 3b 20 
and 3c). Together, these results provide further evidence for activation of TLR7 by 21 
IDT-4 complexed with our liposomes and leading to presentation of DCs and 22 
activation of NK cells and T-cells.  23 
 24 
Pre-treatment with siRNAs impacts tumor formation 25 
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Having established the silencing efficacy and innate immune potential of IDT-4, we 1 
next tested whether this siRNA could impact tumor formation. IDT-12 was included in 2 
this study as this D-siRNA has similar E6/E7 knockdown ability to IDT-4 but lower 3 
immunostimulatory potency (Figure 1c and data not shown), while scrambled D-4 
siRNA was used as a negative control. TC-1 cells stably expressing luciferase (TC-5 
1-luci) were treated with 40nM siRNAs delivered via liposomes for 4 hours at which 6 
time 1×106 cells were subcutaneously injected into each C57BL/6 mouse. Tumors 7 
were allowed to form over 14 days, and caliper measurements were carried out 8 
every two days from the day tumors could be detected from palpation, until the end 9 
of the experiment. On day 14, mice were injected with D-luciferin and the tumors 10 
were imaged by luminescence. Tumors were also collected and weighed at day 14. 11 
Tumors treated with oncogene-specific siRNAs (IDTs-4, -12) appeared to be 12 
substantially smaller than tumors treated with scrambled D-siRNA (Figure 4a). IDT-4 13 
appeared highly effective at impairing tumor development compared to the non-14 
targeting scrambled D-siRNA (Figures 4a, b). Although both target-specific siRNAs 15 
significantly reduced tumor growth compared to scrambled siRNA, there was no 16 
significant difference between the two target specific siRNAs, IDT-4 and IDT-12 17 
(Figure 4c), despite the bifunctional profile of IDT-4. However, this experiment did 18 
not measure the contribution of the innate immune response as TC-1 cells were pre-19 
treated with the siRNAs before inoculation into the mouse, thus macrophage uptake 20 
of siRNAs as well as exposure of siRNAs to circulating and infiltrated tumor 21 
phagocytes did not occur.  22 
 23 
Systemic injection of siRNA results in significant tumor reduction 24 
To test for anti-tumor activity by systemically delivered siRNAs, tumors were 25 
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established in mice by subcutaneous injection of 1×106 TC-1 cells on day 0 followed 1 
by systemic RNAi treatment of 40µg D-siRNA per dose (~2mg/kg) via I.V. tail vein 2 
injection on days 5, 8, and 12. This protocol was performed in parallel to our recently 3 
published studies on liposomal delivery in vivo, which showed substantial siRNA 4 
uptake by target cells using this delivery method 34. To investigate the contribution of 5 
innate immune activation in the anti-tumor effects, we compared the effects of IDT-4 6 
versus IDT-4m7, which had shown no immunostimulatory effect (Figure 5a, b). 7 
Scrambled-m7 was used as a negative control as it had neither silencing nor 8 
immunostimulatory effects (Figure 2a, d). Tumors were measured by caliper on day 9 
10 (Figure 5a) and day 14 (Figure 5b). A significant reduction in tumor size was 10 
observed on day 10 in mice treated with IDT-4 (*P < 0.05) compared to control. 11 
Meanwhile, treatment with IDT-4m7 yielded a 28% reduction in tumor size as 12 
compared to control on day 10, albeit not-significant according to student’s t-test 13 
(Figure 5a). A similar result was obtained on day 14 (Figure 5b), where tumors were 14 
observed to be more significantly reduced in groups treated with oncogene-specific 15 
siRNAs compared to control. This profile is consistent with that obtained in a similar 16 
independent experiment using only half the dose of siRNAs at 20µg siRNA/dose 17 
(~1mg/kg) (Supplementary Figure S2). Although both IDT-4 and IDT-4m7 each 18 
demonstrated significant anti-tumoral effects compared to the control siRNA, the 19 
stronger anti-tumoral effect of IDT-4 (Figures 5a, b; Supplementary Figure S3a) 20 
suggested that its immunostimulatory activity played a significant role in its anti-21 
tumor ability. 22 
 23 
To provide further in vivo evidence that siRNA-induced TLR7 activation could have 24 
an anti-tumoral effect, we tested two siRNAs that are non-specific to HPV and which 25 
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vary widely in their immunostimulatory activity. These were BP1Mod2, which is 1 
strongly immunostimulatory, and ȕgal 924 which has no immunostimulatory activity7 2 
(Figure 5c, d). In accordance with the increased anti-tumoral effect of IDT-4 versus 3 
IDT-4m7, at day 10, we found that the immunostimulatory siRNA BP1 Mod2 4 
exhibited a significant anti-tumor effect (Figure 5c) while the non-targeting and non-5 
immunostimulatory siRNA, ȕgal 924, had no impact on tumor development. 6 
However, this effect was transient as the tumor sizes in BP1 Mod2 returned to 7 
control levels at day 14 (Figure 5d). This result could be attributed to the transient 8 
immunostimulation observed previously (Figure 2e). To examine the possibility that 9 
anti-tumor effects could have been caused by non-specific loss of E6/E7 expression, 10 
we examined E7 protein levels following siRNA treatment and showed that neither 11 
BP1Mod2 nor ȕgal 924 siRNAs altered the levels of HPV16 E7 protein (Figure 5e, 12 
Supplementary Figure S1b). This confirmed that the observed transient anti-tumor 13 
effects of BP1Mod2 seen in Figure 5c were due to innate immune activation alone.  14 
 15 
Finally, to directly establish the role of innate immunity in the anti-tumoral effects 16 
observed at day 10, we examined the impact of IDT-4 and BP1 Mod2 siRNAs in 17 
MyD88 deficient mice35, where TLR7/8 siRNA-induced immunostimulation is ablated 18 
(Figure 5f). Both siRNAs lost significant anti-tumor activity when delivered into 19 
MyD88-/- mice. These preliminary results suggest further the important contribution of 20 
immunostimulation in the anti-tumor effects previously seen with these sequences. 21 
Overall, our data highlights the anti-tumor ability of siRNA-induced 22 
immunostimulation via TLR7, even in the absence of specific gene-silencing.  23 
 24 
 25 
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DISCUSSION 1 
Recent reports have highlighted the ability of siRNAs to induce innate immune 2 
responses via TLR activation 25, 36. Knockdown of an oncogene coupled with an 3 
activation of the tumor immune milieu provides the basis for an elegant co-therapy 4 
for cancer 4. Here we show that activation of the innate immune response by siRNAs 5 
has significant anti-tumor effects against HPV-driven tumors, even in the absence of 6 
a specific gene target. Although the most prolonged siRNA-induced 7 
immunostimulation in our system reached 24 hours, impact on tumor growth was 8 
observed up to 3 days following the last siRNA injection (i.e. on day 10). On the 9 
other hand, oncogene-specific siRNA with immunostimulatory ability gave long term 10 
anti-tumor control with anti-tumor effect observed on day 10 and sustained on day 11 
14. The responses we observed are specific to HPV-driven tumors and one would 12 
expect different cancers to exhibit varying sensitivity to such therapy. This is 13 
illustrated by the work of Poeck et al, who showed that bifunctional siRNAs, 5’-14 
triphosphate-siRNAs (3p-siRNA) targeting Bcl2, led to better melanoma tumor 15 
reduction than OH-siRNA or 5’ triphosphate siRNAs containing target mismatches4.  16 
While Poeck et al  demonstrated that the structure of 3p-siRNA was critical for 17 
activation of immune responses4, the D-siRNAs in our study rely exclusively on 18 
sequence differences to elicit differential TLR activation. Many reports have 19 
suggested that modifications to the siRNA structure impacts its immunostimulatory 20 
ability. Modifications to the siRNA 5’ end with triphosphate 4 or addition of miRNA-21 
like non-pairing uridine bulges to the siRNA backbone 28, 37 increases siRNA-induced 22 
immunostimulation while addition of methyl groups3, 27 removes immunostimulation. 23 
For the D-siRNAs used here, we found that sequence alone play a role in 24 
immunostimulation. However, we observed no consistent sequence motifs in our D-25 
13 
 
siRNAs that resembled known immunostimulatory motifs. Neither the amount of 1 
“GU” motifs nor the overall numbers of U were significantly different7, 26.  However, 2 
IDT-4 does have the “UGUGU” motif, which  Heil et al have reported as 3 
immunostimulatory 26. However, this motif was absent in other highly active siRNAs 4 
(e.g. IDT-5, -6, -8 and -14). We did note that high immunostimulation in these D-5 
siRNAs appeared to be associated with a UXUCU motif starting at position 9 or 10 6 
downstream from the 5’ end of the antisense strand, with IDT-4 having both UXUCU 7 
and UGUGU motifs (Supplementary Figure S3).  8 
 9 
Our study also demonstrates that the immunostimulatory profiles of our D-siRNAs 10 
are similar in vivo to their initial in vitro profiles with IDT-4 consistently demonstrating 11 
the highest level of immunostimulation in both settings. We also observed TLR7 12 
specificity pertaining to siRNA-induced immunostimulation. IDT-4 induced 13 
immunostimulation was concurrent with the activation of DCs and NK cells. 14 
Furthermore, we showed that in vivo induction of IFNĮ by immunostimulatory siRNAs 15 
is transient, lasting 4 to 8 hours. Although we have established that 16 
immunostimulation by our D-siRNAs is sequence-dependent, we also observed that 17 
addition of methyl groups to the antisense strand of these siRNAs abolishes their in 18 
vivo immunostimulatory ability, thus supporting results previously published 3, 27, 37. 19 
However, the RNAi ability by these modified siRNAs was retained, allowing us to 20 
directly compare the effects of TLR7 activation on tumor reduction.   21 
 22 
SiRNAs delivered systemically will target not only to tumor cells, but also to cells of 23 
the liver, lung, and spleen - the primary sites of liposomal deposition 29,34, hence 24 
activating immune cells such as macrophages, dendritic cells and monocytes, 25 
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benefiting anti-tumor activity. To address the activation of these immune cells by 1 
siRNAs, we treated established tumors in mice with systemically-delivered siRNAs 2 
on days 5, 8, and 12, and observed tumor sizes on days 10 and 14. We observed 3 
that siRNA with both RNAi and immunostimulatory abilities gave persistent anti-4 
tumor effects. We suggest that TLR7 activation played a significant role in this tumor 5 
reduction, as loss of TLR7 activity via siRNA sequence modification or ablation of 6 
myD88 pathway impaired this siRNA-mediated tumor reduction. Further, 7 
immunostimulation alone had potent anti-tumor activity as demonstrated by the 8 
activity of BP1 Mod2 on day 10; an effect not seen in MyD88-/- mice treated with this 9 
immunostimulatory siRNA. We also found these non-specific immunostimulatory 10 
effects by BP1 Mod2 to be transient as tumor sizes returned to control levels by day 11 
14. This data point suggests that gene silencing-independent anti-tumor effects 12 
through potential TLR7 activation to be transient.  13 
 14 
The BP1 Mod2 data are consistent with findings from Kleinman et al who showed 15 
that non-targeting siRNAs can have biological activity via activation of TLR3 causing 16 
down-regulation of vascular endothelial growth factor (VEGF) gene in macular 17 
degeneration38. However, the contribution of TLR3 or cytosolic RIG-I to siRNA driven 18 
immunostimulation is minor using a DOTAP-based delivery system 8, 28, as is the 19 
case with our cationic liposomes 29. This suggests that the anti-tumor effects 20 
observed here were due to TLR7 activation. Further work relying on TLR and RIG-I 21 
deficient animal models should help address the direct contribution of TLR3/7 and 22 
RIG-I on assisting tumor reduction and tumor clearance.  23 
 24 
Overall our data show for the first time that siRNA-mediated innate immune 25 
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activation has significant but transient anti-tumor effects in HPV-driven cancers. Our 1 
data suggests that siRNA-induced immunostimulation improved RNAi anti-tumor 2 
ability in HPV-driven tumors. Conversely, abolishing immunostimulation of our 3 
bifunctional siRNA reduced its anti-tumor ability. Further improvements on 4 
bifunctionality may be gained by incorporation of novel sequence modifications that 5 
confer stronger immunostimulatory effects such as addition of uridine bulges recently 6 
reported for human TLR8 activation 28 or by conjugation to a CpG-linker to 7 
incorporate adaptive immune responses for enhanced anti-tumor ability5, 39 in 8 
combination with RNAi in such cancer models. With these improvements, RNAi can 9 
be developed as a single-molecule approach with multiple activities, and could 10 
therefore provide a promising therapeutic strategy against HPV-driven cancers.  11 
 12 
METHODS 13 
Cell lines 14 
Caski cells line was obtained from the American Type Culture Collection (ATCC). 15 
TC-1 cells (murine C57BL/6 lung epithelial cells transformed with HPV16 E6, E7 and 16 
ras oncogenes) were obtained from TC Wu 24. TC-1-luci cells were developed in-17 
house by transducing the luciferase gene into TC-1 cells via lentiviral transfection40. 18 
TC-1 and TC-1-luci cells were maintained in Dulbecco’s modified Eagle’s medium, 19 
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% foetal bovine serum 20 
(FBS) (Bovogen, VIC, AU), 100units/ml penicillin G, 100µg/ml streptomycin sulfate, 21 
and 0.29mg/ml L-glutamine (P/S/G) (Gibco Invitrogen, Mount Waverley, Australia); 22 
referred to as complete DMEM. Caski cells were maintained in Roswell Park 23 
Memorial Institute (RPMI-1640; Invitrogen, Carlsbad, CA) media supplemented as 24 
above; referred to as complete RPMI-1640. Stable TLR7-/- BMMs and TLR2/4-/-  25 
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BMMs were generated using the J2 retrovirus encoding v-raf and v-myc as 1 
previously reported 28, 41, 42, and grown in DMEM with 10% FCS and 20% L-929 2 
conditioned cell medium. Cells were kept at 37°C in a 5% CO2 atmosphere.  3 
 4 
SiRNA 5 
D-siRNAs (Supplementary Table 1) and the modified D-siRNAs (Supplementary 6 
Table 2) used for in vivo experiments were designed22 and supplied by Integrated 7 
DNA Technologies (IDT) (Iowa, USA) as single-stranded, HPLC-purified, lyophilized 8 
sodium salt. They were re-constituted into solution using DEPC water to a 9 
concentration of 100µM. An equal volume of sense and its respective antisense 10 
strand was added to a tube which was heated to 99°C for 10 minutes, and then left 11 
at room temperature for 30 minutes.  Duplexed D-siRNAs were checked on non-12 
denaturing polyacrylamide gels (4.95ml 19:1 Acrylamide/Bis (BioRad, Hercules, CA), 13 
7.05ml dH2O, 3ml 5×TBE (54g Tris, 27.5g Boric Acid, 20ml 0.5M EDTA pH 8), 50µL 14 
10% Ammonium Persulfate (APS), and 15µL 1,2-bis(dimethylamino)-ethane 15 
(TEMED)) and stored as 20µM aliquots for in vitro work and 40µg/5µL for in vivo 16 
work.  SiRNAs s10 1, ȕgal 924 7, and BP1 Mod2 7 were purchased from Sigma-17 
Aldrich (Castle Hill, NSW, Australia) as double-stranded, lyophilized, desalted form 18 
and reconstituted to 100µM using DEPC water.  19 
 20 
Transfection 21 
Caski cells were transfected using Oligofectamine™ reagent (Invitrogen, Mount 22 
Waverley, Australia) according to manufacturer’s instructions. On the day prior to 23 
transfection, cells were plated out at a density of 300,000 cells/well in a 6-well plate. 24 
D-siRNA (1µL of 20µM stock) was diluted in 4µL dH2O, to which 80µL of Opti-MEM I 25 
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reduced-serum media (Invitrogen) was added. For each transfection, 2µL 1 
Oligofectamine™ reagent was added to 13µL Opti-MEM I and incubated at RT for 5 2 
minutes. The mixture was then added to the prepared D-siRNA and the mixture 3 
incubated at room temperature for 20 minutes before being added to 400µL Opti-4 
MEM I and added to cells. After 4 hours incubation at 37°C in 5% CO2 the 5 
transfection mix was removed, cells washed with 1× PBS, and complete RPMI-1640 6 
added and incubation continued overnight at 37°C in a 5% CO2 atmosphere. TC-7 
1/TC-1-luci cells were transfected using cationic liposomes 29 (see below) as follows: 8 
On the day prior to transfection, cells were plated at a density of 100,000 cells/well in 9 
a 6-well plate. D-siRNA (2µL of 20µM stock) was diluted in 3µL dH2O and brought up 10 
to a volume of 100µL with Opti-MEM I reduced-serum media. Cationic liposomes 11 
were diluted in 5% dextrose/dH2O to achieve a liposome to D-siRNA N:P ratio of 4:1 12 
in a final volume of 100µL. The liposome was then added to the D-siRNA and the 13 
mixture incubated at RT for 20 minutes. Liposome/D-siRNA was mixed with 800µL 14 
OptiMEM I before being added to the cells and incubated for 4 hours at 37°C in 5% 15 
CO2. The transfection mix was then removed; cells washed with 1× PBS and 16 
complete DMEM added and incubation continued overnight at 37°C in a 5% CO2 17 
atmosphere. Transfection of control siRNAs were also done in a similar manner to 18 
that described above.  19 
 20 
For transfection of human PBMCs to measure IFNĮ induction, fresh blood from 21 
healthy male donors was collected in heparin-treated tubes, and submitted to ficoll-22 
paque plus (GE Healthcare) gradient purification following the manufacturer's 23 
guidelines (Add reference to our review Gantier and Williams, Methods in Mol. 24 
Biology, 2010). Isolated cells were plated in a 96-well plate at 200,000 cells per well 25 
18 
 
in RPMI 1640+L-glutamine medium (Gibco) complemented with 1X 1 
Antibiotic/Antimycotic (Invitrogen) and 10% FBS (referred to as complete RPMI), and 2 
incubated for 4 hours at 37°C in a 5% CO2 atmosphere prior to stimulation with TLR 3 
agonists. Cells were then transfected with D-siRNAs using DOTAP (Roche, Castle 4 
Hill, Australia) at a DOTAP to siRNA ratio of 5.3 ȝg/ȝl of 80ȝM siRNA. DOTAP was 5 
first diluted in 75ȝl RPMI for 5 minutes before being mixed with an equal volume of 6 
RPMI containing the D-siRNAs. The resulting mix was incubated for at least 10 7 
minutes before 50ȝl was added per well of a 96-well plate, resulting in a final volume 8 
of 150 or 200ȝl.  9 
 10 
For stimulation of mouse bone marrow macrophages with siRNAs, bone marrow 11 
extraction and differentiation were carried out following standard procedures 43. 12 
Briefly, femurs from wild type C57BL/6 mice were flushed with complete RPMI, and 13 
cells were plated in complete RPMI supplemented with 20% L-cells condition 14 
medium44 on 10 cm bacteriological plastic plates for 6 days at 37°C in a 5% CO2 15 
atmosphere. 80,000 cells per 96-well were plated on day 6 in 150uL of complete 16 
RPMI supplemented with 20% L-929 cell conditioned medium. Cells were then 17 
transfected with D-siRNAs/siRNAs using DOTAP (Roche, Castle Hill, Australia) at a 18 
DOTAP to siRNA ratio of 3.74 ȝg/ȝl of 80ȝM siRNA, with D-siRNA concentration of 19 
750nM. 3M-002 (human TLR8 agonist and mouse TLR7 agonist, cat. no. tlrl-C75), 20 
ODN2216 (TLR9 agonist, cat. no. tlrl-hodna),  Pam3CSK4 (TLR2/1 agonist, cat. no. 21 
tlrl-pms), and CL-75 (mouse TLR7 human TLR8 ligand) were used as controls and 22 
purchased from Invivogen (Willoughby, Australia). SiLam-N-MIS was also included 23 
as TLR7-dependent immunostimulatory siRNA in the experiments involving 24 
immortalized BMMs, as previously reported 28.  Controls were added directly to 25 
19 
 
medium and used at a final concentration of 1µg/ml (3M-002), 3µmol/l (ODN2216) 1 
and 100ng/ml (PamSCSK4). Transfections were carried out in triplicate in all 2 
experiments.  3 
 4 
Immunoblotting 5 
Protein extraction was performed on cells 24 hours after transfection. Protein was 6 
extracted using radioimmunoprecipitation assay (RIPA) lysis buffer (150mM NaCl, 7 
0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, and 50mM Tris, pH 8.0) 8 
with the addition of 2mM phenylmethlsulfonyl fluoride (PMSF) and 1µL/mL Protease 9 
Inhibitor Cocktail (PIC) (Sigma, Sydney, Australia). Lysis buffer was freshly prepared 10 
and added to transfected cells in 6-well plates (200µL/well), and incubated for 10 11 
minutes on ice. Protein concentration was determined using protein assay kit (Bio-12 
Rad, Hercules, CA) with the appropriate standards. Cell extracts were boiled for 10 13 
minutes at 99°C in the presence of Loading Buffer (200nM Tris-HCL, 8% SDS, 0.4% 14 
Bromophenol Blue, 40% Glycerol) and ȕ-mercaptoethanol. 60-75µg protein samples 15 
were separated on a 10-15% SDS-PAGE gel, transferred unto Immobilin-P™ 16 
polyvinylidine fluoride (PVDF) membrane (Millipore, Australia) and immunoblotted 17 
using HPV16E7 (Santa Cruz, USA) antibody on the SNAP I.D. system (Millipore, 18 
Australia) according to manufacturer’s instructions. Bound antibodies were detected 19 
using their appropriate secondary antibodies followed by enhanced 20 
chemiluminescence using in-house reagents.  21 
 22 
Quantitative real-time PCR 23 
RNA was extracted from cells using Tri-Reagent (Invitrogen, Auckland, New 24 
Zealand) according to protocol. cDNA synthesis was performed using Omniscript 25 
20 
 
Reverse Transcriptase kit (Qiagen, Hilden, Germany) according to manufacturer’s 1 
protocol. Real-time PCR was carried out using SYBR® Green PCR Master Mix (ABI, 2 
Warrington, UK) according to manufacturer’s protocol with primers as described in 3 
Supplementary Table 3.  4 
The PCR was carried out on Rotorgene 6000 (Corbett) as follows: initial denaturing 5 
at 95°C for 10 minutes, 40 cycles of 95°C for 10 seconds (denature), 60°C for 15 6 
seconds (anneal), and 72°C for 20 seconds (extension), and melt conditions at 75°C 7 
to 95°C rising at 1°C each step. Data was analysed using the Rotor-Gene 6000 8 
series software.  9 
 10 
Detection of cytokines  11 
Human IFNĮ in culture supernatants was quantified by sandwich ELISA using 0.5 12 
ȝg/ml mouse monoclonal (PBL Biomedical) and rabbit polyclonal antibodies (PBL 13 
Biomedical) respectively. A goat anti-rabbit HRP-conjugated antibody (Pierce) at 14 
0.8ȝg/ml was used for detection. Mouse TNFĮ was measured using the BD OptEIA 15 
ELISA set (BD Biosciences, North Ryde, Australia). In both IFNĮ and TNFĮ ELISAs, 16 
TMB substrate (Sigma, Castle Hill, NSW, Australia) was used for quantification of the 17 
cytokines on the Fluostar OPTIMA plate-reader. 18 
 19 
ELISA for murine IFNĮ was performed using Verikine™ Mouse Interferon Alpha (Mu-20 
IFNĮ) ELISA kit (42100-1; PBL Biomedical) according to manufacturer’s protocol and 21 
quantification of cytokine was carried out on the Labsystems Multiskan plate reader.  22 
 23 
In Vitro activation of mouse splenocytes 24 
21 
 
C57BL/6 mice were euthanased by CO2 narcosis and spleens removed under 1 
aseptic conditions. Spleens were then homogenized followed by a 30 minute 2 
incubation with 1 mg/ml Collaginase D, 100 µg/ml DNAse (Roche) at 37°C before 3 
cells were passed through a 70 µM cell strainer (Beckton Dickinson, San Jose, USA) 4 
and red cells removed by a 2 minute incubation with ACK lysing solution. 5 
Splenocytes were then resuspended to 2x106 cells/ml in RPMI1640 media 6 
supplemented with 5% FBS, P/S/G, 1 x 10-3 M Sodium Pyruvate (Gibco) and 5 x 10-5 7 
M 2-mecaptoethanol (Sigma). SiRNA encapsulated in PEGylated Liposomes (as 8 
described below) were added to culture at a final concentration of 90nM.  Isotonic 9 
sucrose was used as a negative control and 25 ng/ml of the TLR7 agonist Imiquimod 10 
(InVivogen, San Diego, CA) was used as a positive control. Cells were incubated for 11 
24 hrs at 37°C before removal from culture and staining with antibodies against 12 
CD3ε-PE, CD11c-APC, CD69-FITC, CD86-PE, NK1.1-APC and MHC class II I-Ab-13 
FITC (Biolegend, San Diego, CA) for 30 minutes on ice. Samples were then washed 14 
and run on a Gallios Benchtop flow cytometer (Beckmann Coulter, Villepinte, 15 
France). Flow cytometry data was analysed using Flowjo7.6 (Flowjo, Ashland, OR).  16 
 17 
Cationic liposomes 18 
For  transfection of TC-1/TC-1-luci cells, cationic liposomes were prepared using 19 
dioleoyl trimethylammonium propane (DOTAP) (Sigma, St Louis, MO) and dioleoyl 20 
phosphatidylethanolamine (DOPE) (Northern Lipids, Vancouver, Canada) at a 1:1 21 
molar ratio as previously described45, resulting in a dried, thin lipid film. The lipid film 22 
was hydrated with sterile 5% dextrose solution to give a final concentration of  23 
2.5x10-6 mole DOTAP/mL. The resulting liposomes was left to stabilize at room 24 
temperature for two hours followed by size reduction of the multilamellar liposomes 25 
22 
 
performed according to the procedure described in Wu et al 29. The resulting small 1 
unilamellar liposomes were subsequently complexed with siRNA at Nitrogen to 2 
Phosphate (N:P) ratios of 4:1 for transfection as described above.   3 
 4 
In vivo experiments 5 
C57BL/6 mice were purchased from Animal Research Centre (ARC) (Perth, WA, 6 
Australia). For delivery of siRNA into C57BL/6 mice and subsequent tumor reduction 7 
experiments, 40µg of each D-siRNA/mouse was complexed with Polyethylene Glycol 8 
(PEG)ylated liposomes according to the  protocol described in Wu et al 29. Briefly, to 9 
prepare the PEGylated liposomes, 0.352mg DOTAP, 0.136mg cholesterol (Sigma, 10 
St Louis, MO), 0.037mg DOPE and 0.263mg PEG2000-C16-ceramide (Avanti Polar 11 
Lipids, Alabaster, AL) were dissolved in tert-butanol at 37°C before the required 12 
volumes of lipids for each D-siRNA to be tested were aliquoted into round-bottomed 13 
flasks. Sterile sucrose solution was prepared and 40µg/mouse D-siRNA was added 14 
to this solution. The D-siRNA/sucrose solution was then added to the lipids solution 15 
and mixed well by gentle shaking. The solution was then snap-frozen in dry 16 
ice/ethanol or acetone bath and lypophilised at least overnight on the freeze-dryer 17 
(ALPHA 1–2 LDplus, Martin Christ, Germany) at a condensing temperature of í80°C 18 
and pressure of less than 0.1 mbar. Once the samples were dry, each sample was 19 
rehydrated with 300µL sterile water per 40µg D-siRNA and allowed to stand at room 20 
temperature for one hour. Control siRNAs were also prepared as described above. 21 
TC-1 cells were subcutaneously injected into female C57BL/6 mice at 1×106 22 
cells/mouse (Day 0). D-siRNAs/siRNAs complexed in liposomes were then injected 23 
intravenously into mice 5, 8, and 12 days after subcutaneous TC-1 tumors were 24 
established. Tumor size was measured using caliper on days 10 and 14. For IFNĮ 25 
23 
 
induction experiments, D-siRNAs/siRNAs complexed in liposomes as above were 1 
injected intravenously into mice and blood collected 4, 8, 24, and 48 hours after I.V. 2 
injection. Serum was then collected according to Sakurai et al 46 and used for mIFNĮ 3 
ELISA. All animal work was approved by The University of Queensland Animal 4 
Ethics Committee, Queensland, Australia.  5 
 6 
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FIGURE LEGENDS 1 
 2 
Figure 1: siRNAs knockdown of HPV16 E6/E7 in cervical cancer cells and 3 
immunostimulatory ability. (a) HPV16 E6/E7 mRNA levels in CaSki cells analysed 4 
by qRT-PCR and normalised against ȕ-actin as a housekeeping gene. Following 5 
transfection with 40nM D-siRNAs for 4 hours, cells were collected 20 hours post-6 
transfection. RNA was extracted from cells and cDNA synthesized and used for 7 
quantitative real-time PCR. Error bar represents ±SEM. Significant differences 8 
between scrambled and siRNAs are indicated (***P < 0.001; two-sided t-test). Data 9 
from two independent experiments each with triplicate samples. (b) HPV16 E6/E7 10 
mRNA levels in TC-1 cells analysed by qRT-PCR and normalised against ȕ-actin as 11 
a housekeeping gene. Following transfection with 40nM of selected D-siRNAs for 4 12 
hours, cells were collected 20 hours post-transfection. RNA was extracted from cells 13 
and cDNA synthesized and used for quantitative real-time PCR. Error bar represents 14 
±SEM. Significant differences between scrambled and siRNAs are indicated (* P < 15 
0.05, **P < 0.01; two-sided t-test). The difference between scrambled and IDT-3 was 16 
not significant according to student’s t-test and noted as “ns”. Data from two 17 
independent experiments with triplicate samples. (c) Fresh human PBMCs from 18 
healthy male donors were treated with 90nM D-siRNAs before supernatants were 19 
collected after 16 hours and IFNĮ detected by ELISA.  CpG DNA (3 µM) and 3M-002 20 
were used as positive control (see Materials and Methods). There were no 21 
detectable levels of IFNĮ in scrambled, mock, and medium samples (noted as “nd”). 22 
Error bar represents ±SEM. Data from two independent experiments with triplicate 23 
samples.  24 
 25 
Figure 2: siRNAs exhibit varying levels of immunostimulation. (a) Mouse bone 26 
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marrow macrophages were stimulated with 90nM siRNA, inclusive of modified 1 
siRNAs, overnight and supernatants were collected after 16 hours before mouse 2 
TNFĮ levels were detected by ELISA. Significant difference between IDT-4 and IDT-3 
4m7 is indicated (*P < 0.05). Error bar represents ±SEM. Data from two independent 4 
experiments with triplicate samples. (b) TLR7-/- immortalized BMMs were stimulated 5 
with 750nM of DOTAP-complexed siRNAs and incubated for 16 hours at 37ºC. 6 
PAM3C (Pam3CSK4), siLam-N-Mis and CL75 were used as controls (see Materials 7 
and Methods). Following overnight stimulation, mouse TNFĮ levels were measured 8 
by ELISA. The difference between IDT-4 and IDT-4m7 is not significant according to 9 
student’s t-test (noted as “ns”). (c) TLR2/4 double knockout cells (TLR7+/+) were 10 
stimulated as described in (b), and mouse TNFĮ levels measured by ELISA. The 11 
significant difference between IDT-4 and IDT-4m7 is indicated (***P <0.001). (b and 12 
c) Error bars represent ±SEM. Data is representative of two independent 13 
experiments in biological triplicate. (d) Following selected siRNA treatment inclusive 14 
of modified IDT-4 (IDT-4m7) and scrambled (scrambled-m7) at 40nM for 4 hours, 15 
TC-1 cells were harvested at 20 hours post transfection and HPV16 E6/E7 mRNA 16 
levels were analysed by qRT-PCR. SiRNA s10 was included as positive control for 17 
gene knockdown. Error bar represents ±SEM. Significant differences between 18 
scrambled-m7 and IDT-4, scrambled-m7 and IDT-4m7 and scrambled-m7 and s10 19 
are indicated (**P < 0.01, ***P < 0.001; two-sided t-test). Data from two independent 20 
experiments with triplicate samples. (e) C57BL/6 mice are treated with a single I.V. 21 
injection containing 40µg siRNA encapsulated in liposomes. Blood was collected 4, 22 
8, 24, and 48 hours post injection. Serum from the blood was collected and murine 23 
IFNĮ (mIFNĮ) levels determined by ELISA. Error bar represents ±SEM with n=3. No 24 
detectable levels of mIFNĮ (marked as “nd”) was observed at 24 and 48 hours for 25 
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samples scrambled, IDT-4 and empty liposome, and no detectable levels of mIFNĮ 1 
was observed at 48 hours for sample BP1 Mod2, a highly-immunostimulatory siRNA 2 
that do not target the HPV16 E6/E7 oncogene.  3 
 4 
Figure 3: Bifunctional siRNA activates DCs and NK cells. Splenocytes were 5 
stimulated with liposome-encapsulated siRNAs at a final concentration of 90nM for 6 
24 hours at 37ºC. Isotonic sucrose and Imiquimod (TLR7 agonist) were used as 7 
controls. Cells were then stained with CD3ε-PE, CD11c-APC, CD69-FITC, CD86-8 
PE, NK1.1-APC and MHC class II I-Ab-FITC and read by flow cytometry. (a) 9 
Presentation of DC on the cells’ surface following siRNA stimulation, represented as 10 
mean fluorescence intensity (MFI). Significant difference between IDT-4 and IDT-11 
4m7 is indicated (*P < 0.05). (b) NK cells’ activation following siRNA stimulation. 12 
Significant difference between IDT-4 and IDT-4m7 is indicated (**P < 0.01). (c) T 13 
cells’ activation following siRNA stimulation. There is no significant difference 14 
between IDT-4 and IDT-4m7 according to student’s t-test (noted as “ns”). Error bar 15 
on all these experiments represents ±SEM. Data from two independent experiments, 16 
each with triplicate samples. 17 
 18 
Figure 4: Pre-treatment of TC-1 cells with siRNAs impacts tumor growth in 19 
vivo.  TC-1 cells were transfected in vitro with 40nM of IDT-4, -12 or scrambled as 20 
control for 4 hours before 1×106 cells were injected subcutaneously into C57BL/6 21 
mice and tumor growth was observed for up to 14 days. (a) Tumors were visualized 22 
on day 14 by injecting mice with D-luciferin and imaging using a Kodak In Vivo 23 
Imager.  (b) Tumor weight was measured on day 14.  Error bar represents ±SEM 24 
with n=5. Significant differences between control and IDT-4, and control and IDT-12 25 
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are indicated (*P < 0.05; two-sided t-test). (c) Tumors were measured by caliper on 1 
subsequent days (days 8, 10, and 13) post initial S.C. injection of tumor cells. Error 2 
bar represents ±SEM with n=5.  3 
 4 
Figure 5: Treatments of established tumors with siRNAs show a reduction in 5 
tumor growth. Treatments of established tumors with intravenously delivered 6 
siRNAs. TC-1 cells (1×106 cells) were subcutaneously injected into C57BL/6 mice on 7 
day 0 before mice were treated intravenously with 40µg siRNAs encapsulated in 8 
liposomes on days 5, 8, and 12. (a-b) Tumor growth reduction by RNAi is 9 
independent of TLR7 activation. Treatments carried out with IDT-4 as an 10 
immunostimulatory D-siRNA and IDT-4m7 as a non-immunostimulatory D-siRNA, 11 
both with RNAi ability for HPV16 E6/E7. Caliper measurements of tumors were 12 
carried out on (a) day 10 and (b) day 14 post initial subcutaneous injections. Error 13 
bar represents ±SEM with n=6. Significant differences between control and IDT-4, 14 
and control and IDT-4m7 are indicated (*P < 0.05, **P < 0.01; two-sided t-test). (c-d) 15 
Activation of TLR7 independent of RNAi results in a transient anti-tumor effect. 16 
Treatments carried out with 40µg siRNA/mouse per I.V. injection as previously 17 
described with BP1 Mod2 (highly immunostimulatory for IFNĮ) and ȕgal 924 (non-18 
immunostimulatory for IFNĮ), both not targeting HPV16 E6/E7. Caliper 19 
measurements of tumors were carried out on (c) day 10 and (d) day 14 post initial 20 
subcutaneous injections. Significant difference between control and BP1 Mod2 is 21 
indicated (***P < 0.001; two-sided t-test). Error bars represents ±SEM with n=5. (e) 22 
Quantification of immunoblots of TC-1 cell lysates in Supplementary Figure S1b 23 
using Image J software. siRNA treated samples in HPV16 E7 blots were corrected 24 
against ȕ-tubulin blots, and compared against untreated samples. Error bar 25 
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represents ±SEM. Significant difference between control and s10 is indicated (*P < 1 
0.05; two-sided t-test). Data from two independent experiments with triplicate 2 
samples. (f) Tumor growth reduction by immunostimulatory siRNA is dependent on 3 
immunostimulation. Treatments carried out with 40µg siRNA/mouse per I.V. injection 4 
as previously described, with IDT-4 as immunostimulatory siRNA targeting E6/E7 5 
and BP1 Mod2 as immunostimulatory siRNA but not targeting E6/E7, in MyD88-6 
knockout mice. Caliper measurements of tumors were carried out on day 10 post 7 
initial subcutaneous injections. Error bars represents ±SEM with n=4. Non-significant 8 
differences were noted as “ns”.  9 
 10 
 11 
 12 
SUPPLEMENTARY FIGURE LEGENDS 13 
 14 
 15 
Figure S1: siRNAs are able to knockdown HPV16 E6/E7 in cervical cancer cells. 16 
Selected D-siRNAs were used to transfect murine lung fibroblast cells harbouring 17 
HPV16 E6/E7, TC-1. (a) Detection of E7 protein by immunoblotting of TC-1 cell 18 
lysates following transfection with 40nM D-siRNAs IDTs -3, -4, -12, -13, and -15 for 4 19 
hours.  Lysates were collected 20 hours post transfection for western blotting. 20 
Controls include untreated TC-1 cells and treatment with a scrambled siRNA, and a 21 
conventional siRNA, s10 as a positive control for gene knockdown. (b) Detection of 22 
E7 protein by immunoblotting of TC-1 cell lysates following transfection with 40nM 23 
non-HPV targeting siRNAs ȕgal 924 and BP1Mod2 siRNAs for 4 hours. SiRNA s10 24 
was used as a positive HPV16 E7 knockdown control and scrambled siRNA used as 25 
a negative knockdown control. Lysates were collected 20 hours post transfection for 26 
western blotting. (a-b) Data is the best representation of at least three independent 27 
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experiments. 1 
 2 
Figure S2: Treatments of established tumors with intravenously delivered 3 
siRNAs. TC-1 cells (1×106 cells) were subcutaneously injected into C57BL/6 mice 4 
on day 0 before mice were treated intravenously with 20µg siRNAs encapsulated in 5 
liposomes on days 5, 8, and 12. (a-b) Tumor growth reduction by RNAi is 6 
independent of TLR7 activation. Treatments carried out with IDT-4 as an 7 
immunostimulatory D-siRNA and IDT-4m7 as a non-immunostimulatory D-siRNA, 8 
both with RNAi ability for HPV16 E6/E7. Caliper measurements of tumors were 9 
carried out on (a) day 10 and (b) day 14 post initial subcutaneous injections. Error 10 
bar represents ±SEM with n=6. Significant differences between control and IDT-4 is 11 
indicated (**P < 0.01; two-sided t-test). Non-significant differences are marked as 12 
“ns”.  13 
 14 
Figure S3: Immunostimulatory motifs for D-siRNAs. A schematic diagram 15 
showing the sequences of highly immunostimulatory D-siRNAs. The sequence motif 16 
UGUGU reported by Heil et al to be immunostimulatory are in bold26, while the motif 17 
consistent with high immunostimulation in D-siRNAs (UXUCU) are in bold and 18 
underlined. IDT-5 has an extra “U” within the motif shown as italicised. The motif 19 
UXUCU was observed starting at position 9 or 10 from the 5’-end of the antisense 20 
strand for D-siRNAs IDTs-5, -6, -8, and -14; while this motif was observed starting at 21 
position 6 from the 5’-end of the antisense strand for IDT-4. IDT-4 was noted to have 22 
both UXUCU and UGUGU motifs, suggesting that these motifs are responsible for its 23 
high immunostimulation profile. We also noted that BP1 Mod2 siRNA used as control 24 
for high immunostimulation has the UGUGU motif7.  25 
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 1 
Supplementary Tables: SiRNAs and qRT-PCR primers used in this study. Table 2 
1: Sequences of siRNAs used in this study. Table 2: Addition of the 2’OMe to the 3 
oligo backbone of IDT-4 and scrambled. Table 3: Primer sequences for qRT-PCR.  4 
 5 






